Minocycline dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Minocycline did not change how long mice lived, in males or females, when started late in life. In 412 people with ALS (Lou Gehrig's disease) it made them worse. In 544 people with mild Alzheimer's disease, two years on it changed nothing.
Evidence grade for Minocycline: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 966 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 966
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
Approved as an antibiotic, including for inflamed acne. Not approved for any brain, nerve or ageing use.
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Brain, memory and mood, Ageing and longevity
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Minocycline is an old antibiotic, mostly used for acne. It was tested as an anti-ageing and brain-protecting drug because it calms immune cells in the brain. It is a prescription drug.
What people take it for
- Acne.
- Calming inflammation in the brain.
- Slowing ageing, based on lab work.
What studies in people showed
For acne, a review of 39 studies with 6,013 people found it works. It was not better than cheaper drugs. In 544 people with mild Alzheimer's disease, two years on it did nothing. In 412 people with ALS, people on it got worse faster than people on a dummy pill. The authors called it harmful. Now the mice. A US program found it did not help mice live longer.
What people report
Reports, not study results
The good
- It clears moderate acne, as shown across 39 studies.
The bad
- In ALS, people on it got worse faster than people on a dummy pill.
- At 400 mg a day in the Alzheimer's study, most people could not stay on it. Only 28.8 percent finished.
- It is linked to drug-caused lupus, and the risk rises the longer you take it.
- Long-term use can stain the skin and gums for good.
Where these come from: The studies and the acne review on this page. We have not collected user reports on this one yet.
My bottom line
It is an acne drug. As a brain or anti-ageing drug, the best human test showed harm. I would not take it for either.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Minocycline has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Memory and thinking554 people · 1 study
- Living longer412 people · 1 study
34 of the 36 indexed goals have no study of any kind behind Minocycline
No study in people, animals or cells on this page reports a result for these. That does not prove Minocycline does nothing for them. It does mean anything you have heard about Minocycline and one of these did not come from a study cited here.
Show full evidence
What is Minocycline?
Minocycline did not change how long mice lived, in males or females, when started late in life. In 412 people with ALS (Lou Gehrig's disease) it made them worse. In 544 people with mild Alzheimer's disease, two years on it changed nothing.
Minocycline got into ageing research because of a good story. It gets into the brain. It calms the brain's immune cells. It stops cells from self-destructing in a dish. And it helped mice with several brain diseases live longer. For about ten years it was one of the most-tested old drugs in brain disease research.
The Interventions Testing Program tested it in a run built around giving rapamycin late in life. The same run tested minocycline, beta-guanidinopropionic acid, MitoQ and 17-DMAG. Rapamycin started at 20 months made mice live longer. None of the other four changed how long mice lived, in either sex.
The human brain disease record is worse than no effect. In a large final-stage study of 412 people with ALS, physical function fell faster on minocycline than on a dummy pill. On the ALS rating scale, people lost 1.30 points a month on the drug, against 1.04 on the dummy. Breathing and deaths leaned the wrong way too, though those gaps could have been chance. The authors said plainly that minocycline was harmful, and that this mattered for the other brain disease studies then running.
One of those studies reported in 2020. 544 people with mild Alzheimer's disease took 200 mg, 400 mg or a dummy pill for 24 months. Their memory test scores fell 4.1 points on minocycline and 4.3 points on the dummy. No benefit. And the 400 mg dose was so hard to take that only 28.8 percent finished it.
What minocycline does reliably is treat acne. A Cochrane review pooled 39 studies with 6,013 people. It works for moderate red, swollen acne. There was no sign it beats cheaper drugs, and it has a safety worry of its own.
How does Minocycline work?
It is an antibiotic. It kills bacteria by jamming the machinery they use to make proteins. That is not why it was tested for ageing. It was tested because of its other effects. It gets into the brain and spinal cord. It calms the brain's immune cells and blocks some enzymes that damage tissue. In a dish, it stops cells from self-destructing. Those effects are real in cells. But the ALS study is the clearest case on this site of an idea that worked in cells and in sick mice, and then harmed patients.
What have studies in people found about Minocycline?
A lot of human data, and mostly bad news outside skin care. Two large brain disease studies, one showing harm and one showing nothing. A Cochrane review confirms a real but ordinary benefit for acne.
- Acne, 39 studies with 6,013 people: it works, but not better than cheaper drugs.
- Mild Alzheimer's disease, 544 people over 24 months: no difference in thinking or daily life at either dose.
- ALS, 412 people: physical function fell faster on minocycline than on a dummy pill. The study authors called the effect harmful.
- Minocycline in particular, not the other drugs in its family, is linked to drug-caused lupus. That is about 8.8 cases per 100,000 people per year of use, and the risk rises the longer it is taken.
- Long-term use can stain the skin and gums for good. That is part of why it is used less often as a first choice for acne.
- No human study has looked at lifespan or healthy ageing.
What this does not tell you: There is no human ageing data at all. What the human record gives instead is a warning about the idea behind it. The same calming, cell-protecting effects that made it a lifespan candidate were tested head-on in a brain disease, and the treated group did worse. That does not automatically apply to healthy people at lower doses. But it is the most useful safety information there is.
The state of the research
When this program finds no lifespan effect, that is a real, costly, careful result. It is also narrower than it sounds. It tested one amount in the food, started at one age, in one kind of mouse, and it counted deaths. A no-effect result tells you that this dose, in these mice, did not change how long they lived. It does not tell you the compound does nothing. It does not tell you a different dose would fail, that the idea behind it is wrong, or that the reason people actually take it has been disproved. Those are separate questions, and most were never asked. This site tries to avoid mistakes in both directions. A mouse lifespan win is not proof a supplement works. A mouse lifespan miss is not proof it does nothing.
Minocycline is the page where the mouse result is the least interesting thing. A mouse lifespan study that finds nothing leaves the question open. A 412-person study where the treated group got worse faster does not.
It is also a lesson in how an idea gains trust without ever being tested where it counts. Minocycline calmed brain immune cells in a dish, protected nerve cells in culture, and helped mice with brain diseases live longer. On that basis it went into human studies in ALS, Parkinson's disease, multiple sclerosis, stroke and Alzheimer's disease. The two biggest to report found harm and nothing. The mouse lifespan result came later and fits with both.
The Interventions Testing Program is paid for by the US National Institute on Aging. It runs each test at three separate labs at the same time, in Bar Harbor, Ann Arbor and San Antonio. It uses a mixed breed of mice, a cross of four strains, so no result can come from one odd strain. It tests males and females. Each group is big enough to spot about a 10 percent change in lifespan. Each compound is mixed into the food from a set age. And the program promises in advance to publish results that show nothing, alongside the ones that work. That promise is why this page can exist. Almost nothing else in ageing research reliably tells you what did not work.
The evidence, in charts
Fig. 1a · how many people
966people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| JAMA Neurology 2020 | 554 | 57% |
| Lancet Neurology 2007 | 412 | 43% |
One study holds 57% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 4 sources here are studies in people. The rest are not.
- Study in people · done in people250%
- Animal study · done in animals125%
- Review of studies · sums up other studies125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2007 to 2020, counted from the list of sources on this page. The newest source on file is from 2020, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 457.5 Da. A tetracycline, not a peptide.
- Half-life
- About 16 hoursMedium, 6 to 24 hours
- Chain length
- None on file
Half-life as stated on file: About 16 hours, which is long for a tetracycline and is why it is dosed once or twice daily.
No amino acid sequence is on file for Minocycline, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2007Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
This drug did not simply fail in ALS. People got worse on it. 412 patients were split by chance to a dummy pill or minocycline built up to 400 mg a day for nine months. Those on minocycline lost physical function faster than those on the dummy. Breathing capacity, muscle strength and deaths all leaned the wrong way too, though those gaps were small enough to be chance. The authors called the effect harmful and said it should change how the drug is tested in other brain diseases.
412 patients randomised to placebo or escalating minocycline up to 400 mg per day for nine months. ALSFRS-R deterioration was faster on minocycline, -1.30 against -1.04 units per month (p equals 0.005), with non-significant trends toward faster decline in forced vital capacity and muscle testing and greater mortality (hazard ratio 1.32). The authors concluded minocycline had a harmful effect with implications for its trials in other neurological disorders.
- Study in people2020Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial
Tested properly in mild Alzheimer's disease, and it did nothing. 554 people at 32 UK memory clinics were assigned by chance to 400 mg of minocycline, 200 mg, or a dummy pill for two years. Thinking scores fell by roughly four points in every group. Day to day function worsened at the same rate as well. A trial this size would have found a real benefit. Only 28.8 percent finished the high dose against 63.7 percent on the dummy, because most people could not stay on it.
554 randomised, 544 analysed, across 32 NHS memory clinics, 24 months of 400 mg, 200 mg or placebo. Standardised MMSE decline was 4.1 points in the combined minocycline groups against 4.3 on placebo, a difference of 0.1 points (95 percent CI -1.1 to 1.2, p equals 0.90). Activities of daily living worsened equally. Only 28.8 percent completed the 400 mg arm against 63.7 percent on placebo.
- Review of studies2012Minocycline for acne vulgaris: efficacy and safety
A review that pooled 39 studies with 6,013 people. Minocycline works for moderate to fairly bad red, swollen acne. There was no sign it works better than other common acne drugs. It had more serious side effects than doxycycline. It is linked to drug-caused lupus, and that risk grows the longer you take it. Slow-release pills were not shown to be any safer.
39 randomised trials, 6,013 participants. Minocycline is effective for moderate to moderately severe inflammatory acne, with no evidence it is superior to other commonly used treatments. The review reports more severe adverse effects than doxycycline, an association with drug-induced lupus erythematosus at roughly 8.8 cases per 100,000 person-years rising with duration of use, and no support for the claim that extended-release preparations are safer.
- Animal study2020Rapamycin-mediated mouse lifespan extension: Late-life dosage regimes with sex-specific effects
In mice. This test run was built around giving rapamycin late in life, from 20 months. Rapamycin made male and female mice live longer. Four other drugs were tested the same way, including minocycline. None of them changed how long mice lived, in either sex.
Interventions Testing Program cohort comparing three late-life rapamycin regimens started at 20 months. Rapamycin at 42 ppm increased survival in both sexes. The same experimental design tested four other drugs, minocycline, beta-guanidinopropionic acid, MitoQ and 17-DMAG, and none of these led to a change in survival in either sex.
Common questions
Has Minocycline been tested in people?
Yes. 966 people given it across 2 completed trials cited here, 0 of which found nothing. Minocycline did not change how long mice lived, in males or females, when started late in life. In 412 people with ALS (Lou Gehrig's disease) it made them worse. In 544 people with mild Alzheimer's disease, two years on it changed nothing.
What is the Minocycline dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. Approved as an antibiotic, including for inflamed acne. Not approved for any brain, nerve or ageing use.
Is Minocycline FDA-approved?
Approved as an antibiotic, including for inflamed acne. Not approved for any brain, nerve or ageing use.
Is minocycline a longevity drug?
No. The National Institute on Aging fed it to mixed-breed mice and survival did not change in either sex. There is no human ageing data. The biggest human brain disease study found the treated group got worse faster than people on a dummy pill.
Why was an antibiotic tested for ageing at all?
Not to kill germs. Minocycline gets into the brain, calms the brain's immune cells, and stops cells from self-destructing in a dish. It also helped mice with several brain diseases live longer. Swelling in the brain is a believable cause of ageing, so it was a fair thing to test.
Did it actually harm people?
In ALS, yes. In 412 patients, physical function on the ALS rating scale fell 1.30 points a month on minocycline, against 1.04 on a dummy pill. That gap was too big to be chance, and the authors called the effect harmful. That finding is for that disease and that dose. It is the reason to doubt the brain-protection story.
Does it still work for acne?
Yes, for moderate red, swollen acne. 39 studies back that up. The Cochrane review found no sign it beats other common acne drugs. It also flagged a small but real link to drug-caused lupus, which rises the longer you take it.